Tricida
Menlo Park
About Tricida
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $624.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Oct 2022)
- Ticker: nasdaq:TCDA
- Website: tricida.com
- Phone: 415-429-7800
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tricida-111276 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.